growth



BUY TP: Rs 2,541 | ^ 29% MPI

sequential uptick from Q2FY24

MPHASIS

Dull quarter; sequential recovery guided from Q2

Technology & Internet

29 May 2023

Saptarshi Mukherjee research@bobcaps.in

Current deal TCV can support US\$ 120mn+ incremental revenue over FY23-FY25E; we assume coverage with BUY and a TP of Rs 2,541

Growth in direct business likely to be back-ended with strong

Weak Q4 revenue print (-4.1% QoQ); DR and DXC remained a drag on

Q4 weak: MPHL reported a dollar revenue decline of 4.1% QoQ (4.5% QoQ CC) in Q4FY23, much below consensus estimates of a 0.3% QoQ dip. Growth was adversely impacted by a 3.4% QoQ CC decline in direct international business (owing to a 26% QoQ drop in Digital Risk – DR). DXC, which forms 3.8% of revenue, fell 25% QoQ CC following some stability in the last two quarters.

Mortgage business to stabilise in Q2: MPHL has historically gained market share from peers (especially in BFSI), but management expects tighter spends and lower conversions to limit share gains and increase the ask-rate for bookings (which was lower in Q4 adjusted for large deals). That said, mortgage business represented by DR still forms 7% of MPHL's revenue and has largely bottomed out, per management.

Portfolio diversification via non-BFSI deal pipeline: Net new deal TCV of direct international business stood at US\$ 309mn (including a US\$ 150mn deal in BFSI) in Q4, taking the FY23 bookings to US\$ 1.3bn (-8% YoY). The pipeline is up 9% QoQ and 35% YoY, but pipeline to TCV conversion is slowing due to delayed decision-making. TCV to revenue conversion has also slowed to 0.8x vs. 0.9x in Q4FY22.

Margin to stay range-bound in FY24: EBIT margin was flat sequentially at 15.3% as the impact of lower revenue was mitigated by higher offshore utilisation and fresher deployment. MPHL expects the softness in BFS to continue in Q1FY24 and is guiding for margins within a range of 15.25-16.25% for all the quarters of FY24, led by a focus on pyramid optimisation, better utilisation and offshore leverage. Offshore utilisation including trainees is at 75% vs. the previous peak of 83-84%.

BUY, TP Rs 2,541: The stock is currently trading at 20.6x/17.3x FY24E/FY25E EPS. We expect MPHL to perform well led by (i) DR and DXC combined run rate (US\$ 173mn on annualised run-rate in Q4), and (ii) strong net new TCV at >US\$ 1bn+ (5Y average) that can support US\$ 120mn+ in incremental revenue over FY23-FY25E. We thus assume coverage on MPHL with BUY and have a TP of Rs 2,541, valuing the stock at 22.2x FY25E EPS – in line with the 3Y mean.

Key changes

	Target	Rating		
	•			
Ticke	er/Price	MPHL IN/Rs 1,975		
Mark	et cap	US\$ 4.5bn		
Free	float	40%		
3M ADV		US\$ 12.5mn		
52wk high/low		Rs 2,700/Rs 1,660		
Prom	noter/FPI/DII	52%/29%/14%		

Source: NSE | Price as of 26 May 2023

Key financials

Y/E 31 Mar	FY23P	FY24E	FY25E
Total revenue (Rs mn)	1,37,984	1,50,662	1,76,874
EBITDA (Rs mn)	24,239	27,119	31,838
Adj. net profit (Rs mn)	16,297	17,878	21,384
Adj. EPS (Rs)	87.2	95.7	114.4
Consensus EPS (Rs)	87.2	96.3	115.8
Adj. ROAE (%)	21.9	22.0	25.3
Adj. P/E (x)	22.6	20.6	17.3
EV/EBITDA (x)	15.3	13.6	11.5
Adj. EPS growth (%)	13.9	9.7	19.6

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

Stock performance



Source: NSE






Fig 1 – Quarterly performance

(mn)	Q4FY23	Q3FY23	Q4FY22	QoQ (%)	YoY (%)	FY23	FY22	YoY (%)
US\$ Revenue	409	426	435	(4.1)	(6.1)	1,712	1,606	6.6
INR Revenue	33,612	35,062	32,777	(4.1)	2.5	1,37,985	1,19,614	15.4
EBIT	5,152	5,354	4,973	(3.8)	3.6	21,087	18,269	15.4
PAT	4,053	4,123	3,921	(1.7)	3.4	16,379	14,309	14.5
EBIT Margin (%)	15.3	15.3	15.2	6bps	16bps	15.3	15.3	(0.3bps)
PAT Margin (%)	12.1	11.8	12.0	30bps	10bps	11.9	12.0	(20bps)


Source: Company, BOBCAPS Research

Fig 2 – Employee matrix




Source: Company, BOBCAPS Research

Fig 4 – Revenue by geography (INR mn)




Source: Company, BOBCAPS Research

Fig 6 – Net new deal TCV (Direct business]




Source: Company, BOBCAPS Research

Fig 3 – Client breakup



Source: Company, BOBCAPS Research

Fig 5 – Revenue by service type (INR mn)



Source: Company, BOBCAPS Research



Earnings call highlights

- Though mortgage rates have started to decline, MPHL indicated that consumer demand for mortgage remains uncertain. Its mortgage vertical exposure has come down from 8.8% in Q3FY23 to 6.8% in Q4FY23.
- The company is seeing a delay in conversion of deal wins to revenue because of a slowdown in decision-making and weakness in the mortgage space.
- Management expects a soft beginning in Q1FY24 due to client-specific issues in BFS and delayed contract conversion in the current environment. The company expects the mortgage business to bottom out by the end of Q1 and stability to return from Q2 onwards.
- Of the total contract value (TCV) in Q4FY23, MPHL indicated that 70% came from BFSI, 15% from insurance, 9% from TMT and 4% from logistics & transportation. TCV has held above US\$ 300mn for all the four quarters of FY23, and management is confident of maintaining this run-rate in FY23.
- DXC revenue declined 24.8% QoQ CC and now accounts for 3.8% of the topline vs. 4.8% in Q3FY23 and 5.2% in Q4FY22. Management expects DXC revenue share to stabilise at these levels.
- Geography-wise, US revenue (80.8% of the mix) declined 5.3% QoQ in Q4 while EMEA (10.7%) and India (5.5%) grew 1.4% and 3.6% QoQ respectively.
- Vertical-wise, BFS (53.1% of the mix), insurance (7.6%) and telecom, media & technology (TMT: 12.7%) declined 5.1%, 11.3% and 6.1% QoQ respectively. Logistics & transportation grew 0.6% and other verticals grew 2% QoQ.
- The company is seeing traction (i) in the areas of modern engineering practices & developer productivity, and (ii) in areas that use automation elements such as contact centre automation that uses digital self-help and chatbots.
- MPHL is looking at M&A as a strategic tool to diversify it vertical and geography base, with some deals under discussion and a few at the diligence stage.



Valuation methodology

The stock is currently trading at 20.6x/17.3x FY24E/FY25E EPS. We expect MPHL to perform well led by (i) DR and DXC combined run rate (US\$ 173mn on annualised runrate in Q4), and (ii) strong net new TCV at >US\$ 1bn+ (5Y average) that can support US\$ 120mn+ in incremental revenue over FY23-FY25E. We thus assume coverage on MPHL with BUY and have a TP of Rs 2,541, valuing the stock at 22.2x FY25E EPS - in line with the three-year mean of its one-year forward P/E multiple.





Source: Company, BOBCAPS Research

Key risks

Key downside risks to our estimates are:

- extension of the global macro downcycle beyond CY23,
- further hike in interest rates globally, leading to lower valuation multiples and further downside risk to mortgage business revenue, and
- weakness in BFSI vertical due to tepid credit demand.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Affle (India)	AFFLE IN	0.3	925	1,110	BUY
Coforge	COFORGE IN	3.4	4,460	4,830	BUY
HCL Technologies	HCLT IN	37.6	1,139	1,240	BUY
Infosys	INFO IN	67.4	1,317	1,760	BUY
Mphasis	MPHL IN	4.5	1,975	2,541	BUY
Persistent Systems	PSYS IN	5.0	5,089	5,330	BUY
Tata Consultancy Services	TCS IN	148.2	3,329	3,580	HOLD
Tech Mahindra	TECHM IN	11.8	1,115	1,130	HOLD
Wipro	WPRO IN	26.8	402	420	HOLD

Source: BOBCAPS Research, NSE | Price as of 26 May 2023



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Total revenue	97,223	1,19,614	1,37,984	1,50,662	1,76,874
EBITDA	18,028	21,175	24,239	27,119	31,838
Depreciation	2,418	2,906	3,253	3,594	3,657
EBIT	15,610	18,269	20,986	23,525	28,180
Net interest inc./(exp.)	0	0	0	0	1
Other inc./(exp.)	696	861	644	312	332
Exceptional items	0	0	0	0	0
EBT	16,306	19,130	21,630	23,837	28,512
Income taxes	4,139	4,821	5,333	5,959	7,128
Extraordinary items	0	0	0	0	1
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	12,167	14,309	16,297	17,878	21,384
Adjustments	0	0	0	0	1
Adjusted net profit	12,167	14,309	16,297	17,878	21,384

Balance Sheet					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Accounts payables	0	0	0	0	0
Other current liabilities	11,927	18,573	19,797	22,703	26,652
Provisions	3,494	5,160	4,115	6,192	7,269
Debt funds	11,811	12,519	10,528	10,528	10,528
Other liabilities	342	718	1,030	1,030	1,030
Equity capital	1,870	1,878	1,884	1,884	1,884
Reserves & surplus	63,398	67,554	77,464	81,120	84,344
Shareholders' fund	65,268	69,432	79,348	83,004	86,228
Total liab. and equities	92,842	1,06,402	1,14,818	1,23,456	1,31,707
Cash and cash eq.	11,310	9,682	10,558	12,324	12,602
Accounts receivables	8,147	8,523	8,523	12,383	14,538
Inventories	0	0	0	0	0
Other current assets	23,437	30,605	34,867	39,214	46,036
Investments	18,460	18,130	17,526	17,526	17,526
Net fixed assets	8,870	10,388	11,012	9,678	8,674
CWIP	31	110	324	324	324
Intangible assets	21,326	27,348	29,586	29,586	29,586
Deferred tax assets, net	1,261	1,616	2,422	2,422	2,422
Other assets	0	0	0	0	0
Total assets	92,842	1,06,402	1,14,818	1,23,456	1,31,707

Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Cash flow from operations	11,528	17,122	14,823	17,936	20,760
Capital expenditures	(1,477)	(2,439)	(836)	(2,260)	(2,653)
Change in investments	3,702	0	0	0	0
Other investing cash flows	696	(1,139)	(2,356)	(3,688)	(3,668)
Cash flow from investing	2,921	(3,578)	(3,192)	(5,948)	(6,321)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	(2,356)	(1,687)	0	0	0
Dividends paid	(14,623)	(9,475)	(10,792)	(11,839)	(14,161)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(16,979)	(11,163)	(10,792)	(11,839)	(14,161)
Chg in cash & cash eq.	(2,530)	2,381	839	149	278
Closing cash & cash eq.	8,955	11,336	12,175	12,324	12,602

Per Share					
Y/E 31 Mar (Rs)	FY21A	FY22A	FY23P	FY24E	FY25E
Reported EPS	65.1	76.6	87.2	95.7	114.4
Adjusted EPS	65.1	76.6	87.2	95.7	114.4
Dividend per share	65.0	42.1	48.0	52.6	62.9
Book value per share	349.3	371.6	424.7	444.2	461.5
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23P	FY24E	FY25E
EV/Sales	3.8	3.1	2.7	2.4	2.1
EV/EBITDA	20.5	17.5	15.3	13.6	11.
Adjusted P/E	30.3	25.8	22.6	20.6	17.3
P/BV	5.7	5.3	4.7	4.4	4.3
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23P	FY24E	FY25
Tax burden (Net profit/PBT)	74.6	74.8	75.3	75.0	75.
Interest burden (PBT/EBIT)	104.5	104.7	103.1	101.3	101.3
EBIT margin (EBIT/Revenue)	16.1	15.3	15.2	15.6	15.9
Asset turnover (Rev./Avg TA)	108.5	120.1	124.7	126.5	138.
Leverage (Avg TA/Avg Equity)	1.5	1.5	1.5	1.5	1.
Adjusted ROAE	19.7	21.2	21.9	22.0	25.
Ratio Analysis					
Y/E 31 Mar	FY21A	FY22A	FY23P	FY24E	FY25
YoY growth (%)					
Revenue	9.9	23.0	15.4	9.2	17.4
EBITDA	9.2	17.5	14.5	11.9	17.4
Adjusted EPS	2.7	17.6	13.9	9.7	19.0
Profitability & Return ratios (%)					
EBITDA margin	18.5	17.7	17.6	18.0	18.
EBIT margin	16.1	15.3	15.2	15.6	15.
Adjusted profit margin	12.5	12.0	11.8	11.9	12.
Adjusted ROAE	19.7	21.2	21.9	22.0	25.
ROCE	18.5	19.6	20.6	21.7	25.3
Working capital days (days)					
Receivables	29	25	23	25	2
Inventory	0	0	0	0	
Payables	63	70	71	68	7
•					
Ratios (x)					
()	11.0	12.4	12.9	14.6	19.3
Gross asset turnover	11.0 2.8	12.4 2.1	12.9 2.3	14.6 2.2	19.: 2.:
Ratios (x) Gross asset turnover Current ratio Net interest coverage ratio					

Adjusted debt/equity 0.0 0.0 Source: Company, BOBCAPS Research | Note: TA = Total Assets 0.0

0.0

0.0



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704**, **B Wing**, **Parinee Crescenzo**, **G Block**, **BKC**, **Bandra East**, **Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): MPHASIS (MPHL IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employeed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company, except for Research Analyst Saptarshi Mukherjee having 20 shares of Infosys (INFO IN). BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collective), the "Losses" which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.